Literature DB >> 30676296

No end to the crisis without an end to the waiver.

Joseph W Frank1,2, Sarah E Wakeman3,4, Adam J Gordon5,6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30676296     DOI: 10.1080/08897077.2018.1543382

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


× No keyword cloud information.
  15 in total

1.  ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.

Authors:  Ryan Marino; Jeanmarie Perrone; Lewis S Nelson; Timothy J Wiegand; Evan S Schwarz; Paul M Wax; Andrew I Stolbach
Journal:  J Med Toxicol       Date:  2019-08-14

2.  Increasing Access to Medications for Opioid Use Disorder and Complementary and Integrative Health Services in Primary Care.

Authors:  Evelyn T Chang; Rebecca S Oberman; Amy N Cohen; Stephanie L Taylor; Elisa Gumm; Aram S Mardian; Shawn Toy; Araceli Revote; Britney Lewkowitz; Elizabeth M Yano
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

3.  A Call to Action: Hospitalists' Role in Addressing Substance Use Disorder.

Authors:  Honora Englander; Kelsey C Priest; Hannah Snyder; Marlene Martin; Susan Calcaterra; Jessica Gregg
Journal:  J Hosp Med       Date:  2019-10-23       Impact factor: 2.960

4.  Buprenorphine Waiver Attitudes Among Primary Care Providers.

Authors:  Benjamin Lai; Ivana Croghan; Jon O Ebbert
Journal:  J Prim Care Community Health       Date:  2022 Jan-Dec

5.  A bifurcated opioid treatment system and widening insidious disparities.

Authors:  Erick G Guerrero; Hortensia Amaro; Tenie Khachikian; Mona Zahir; Jeanne C Marsh
Journal:  Addict Behav       Date:  2022-03-02       Impact factor: 4.591

6.  "Now hospital leaders are paying attention": A qualitative study of internal and external factors influencing addiction consult services.

Authors:  Kelsey C Priest; Honora Englander; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2019-12-05

7.  Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories.

Authors:  Irineo Cabreros; Beth Ann Griffin; Brendan Saloner; Adam J Gordon; Rose Kerber; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

8.  Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US.

Authors:  Bradley D Stein; Brendan Saloner; Megan S Schuler; Jill Gurvey; Mark Sorbero; Adam J Gordon
Journal:  JAMA       Date:  2021-06-01       Impact factor: 56.272

Review 9.  Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.

Authors:  Amanda J Abraham; Christina M Andrews; Samantha J Harris; Peter D Friedmann
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

10.  It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.

Authors:  Brendan Saloner; Barbara Andraka Christou; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2021-04-02       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.